ArticleBiomaterials2011
Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Impact of antigen loading in tolerogenic nanoparticles to mitigate Th2-mediated allergic lung inflammation.Drug delivery and translational research · 2024Article
- Localized drug delivery graphene bioscaffolds for cotransplantation of islets and mesenchymal stem cells.Science advances · 2021Article
- Effect of alginate matrix engineered to mimic the pancreatic microenvironment on encapsulated islet function.Biotechnology and bioengineering · 2021Article
- A Collagen Based Cryogel Bioscaffold that Generates Oxygen for Islet Transplantation.Advanced functional materials · 2020Article
- An elastin-based vasculogenic scaffold promotes marginal islet mass engraftment and function at an extrahepatic site.Journal of immunology and regenerative medicine · 2019Article
- Engineering Immune Tolerance with Biomaterials.Advanced healthcare materials · 2019Review
- Microporous Polymer Scaffolds for the Transplantation of Embryonic Stem Cell Derived Pancreatic Progenitors to a Clinically Translatable Site for the Treatment of Type I Diabetes.ACS biomaterials science & engineering · 2018Article
- Polymeric Scaffolds for Pancreatic Tissue Engineering: A Review.The review of diabetic studies : RDS · 2018Review
- Pancreatic islet macroencapsulation using microwell porous membranes.Scientific reports · 2017Article
- Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice.Transplantation · 2017Article
- In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Advanced drug delivery reviews · 2017Review
- Article
- Regulatory T cell-based therapies for autoimmunity.Discovery medicine · 2016Review
- Controlled release strategies for modulating immune responses to promote tissue regeneration.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.Clinical immunology (Orlando, Fla.) · 2015Review
- Engineering biomimetic materials for islet transplantation.Current diabetes reviews · 2015Review
- Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection.Cell transplantation · 2015Article
- Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice.Journal of immunology research · 2015Article
- Overcoming immunological barriers in regenerative medicine.Nature biotechnology · 2014Article
- Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Allogeneic islet cell transplantation is a promising treatment for human type 1 diabetes. Currently, human islets are transplanted via intra-portal infusions. While successful, it leads to significant early islet attrition from instant blood-mediated inflammatory reaction. An extra-hepatic site was established by transplanting islet-loaded microporous poly(lactide-co-glycolide) (PLG) scaffolds into the epididymal fat pad in syngeneic islet transplant models. This study examined this technology in allogeneic islet transplantation and determined whether transplant tolerance could be effectively induced to protect PLG scaffold transplanted allogeneic islets. The efficacy of an established tolerance induction strategy using donor splenocytes treated with ethylcarbodiimide(ECDI) was tested. ECDI-fixed donor splenocytes were infused 7 days before and 1 day after islet transplantation. Immediate normoglycemia was restored, and treated mice maintained indefinite normoglycemia whereas untreated mice rejected islet grafts within 20 days of transplantation. Interestingly, efficacy of tolerance induction was superior in PLG scaffold compared with intra-portal transplanted islets. Protection of PLG scaffold islet allografts was associated with several mechanisms of immune regulation. In summary, PLG scaffolds can serve as an alternative delivery system for islet transplantation that does not impair tolerance induction. This approach of combining tolerance induction with scaffold islet transplantation has potential therapeutic implications for human islet transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.